Vascular endothelial growth factor (VEGF), prostaglandin E2(PGE2) and active renin in hypertension of adrenal origin

被引:11
作者
Zacharieva, S [1 ]
Atanassova, I [1 ]
Orbetzova, M [1 ]
Kirilov, G [1 ]
Nachev, E [1 ]
Kalinov, K [1 ]
Shigarminova, R [1 ]
机构
[1] Med Univ Sofia, Clin Ctr Endocrinol & Gerontol, Sofia 1303, Bulgaria
关键词
vascular endothelial growth factor; PGE(2); active renin; angiogenesis; adrenal hypertension;
D O I
10.1007/BF03347516
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There are limited data regarding the role of vascular endothelial growth factor (VEGF) in arterial hypertension. The aim of the present study was to determine some markers of vascular function, including VEGF, active renin and prostaglandin E-2 (PGE(2)) in patients with endocrine hypertension. The study comprised: 30 patients with primary aldosteronism; 32 patients with active Cushing's syndrome; 19 patients with pheochromocytoma; 22 patients with essential hypertension and 24 healthy volunteers. VEGF was significantly elevated in all groups of patients as compared to the controls. VEGF levels in patients with Cushing's syndrome were significantly higher than those in patients with essential hypertension and primary aldosteronism. We did not find significant differences in VEGF levels between patients with Conn adenomas and idiopathic aldosteronism as well as between patients with Cushing's disease and Cushing's syndrome. PGE(2) levels were not significantly different among the groups. Active renin was significantly the lowest in patients with primary aldosteronism and significantly the highest in those with pheochromocytoma compared to controls. The level of active renin in patients with primary aldosteronism was significantly lower than in patients with Cushing's syndrome and pheochromocytoma. In conclusion, VEGF levels were significantly elevated in patients with endocrine hypertension due to glucocorticoid, mineralocorticoid and/or catecholamine excess. The highest VEGF levels were detected in patients with Cushing's syndrome. The latter is associated with accelerated development of atherosclerosis and increased cardiovascular risk. VEGF might contribute to the cardiovascular risk in this disease. This effect was not likely to be PGE(2) mediated. (C) 2004, Editrice Kurtis.
引用
收藏
页码:742 / 746
页数:5
相关论文
共 35 条
[1]   Plasma levels of vascular endothelial growth factor and its soluble receptor (sFlt-1) in essential hypertension [J].
Belgore, FM ;
Blann, AD ;
Li-Saw-Hee, FL ;
Beevers, DG ;
Lip, GYH .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (06) :805-+
[2]   Angiogenesis in human normal and pathologic adrenal cortex [J].
Bernini, GP ;
Moretti, A ;
Bonadio, AG ;
Menicagli, M ;
Viacava, P ;
Naccarato, AG ;
Iacconi, P ;
Miccoli, P ;
Salvetti, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (11) :4961-4965
[3]   Vascular endothelial growth factor increases the migration and proliferation of smooth muscle cells through the mediation of growth factors released by endothelial cells [J].
Cucina, A ;
Borrelli, V ;
Randone, B ;
Coluccia, P ;
Sapienza, P ;
Cavallaro, A .
JOURNAL OF SURGICAL RESEARCH, 2003, 109 (01) :16-23
[4]   Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth [J].
Egami, K ;
Murohara, T ;
Shimada, T ;
Sasaki, K ;
Shintani, S ;
Sugaya, T ;
Ishii, M ;
Akagi, T ;
Ikeda, H ;
Matsuishi, T ;
Imaizumi, T .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (01) :67-75
[5]  
Eppler SM, 2000, J AM COLL CARDIOL, V35, p73A
[6]   Angiogenesis and vascular architecture in pheochromocytomas - Distinctive traits in malignant tumors [J].
Favier, J ;
Plouin, PF ;
Corvol, P ;
Gasc, JM .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 161 (04) :1235-1246
[7]   Physical activity in relation to indices of endothelial function and angiogenesis factors in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) [J].
Felmeden, DC ;
Spencer, CGC ;
Blann, AD ;
Beevers, DG ;
Lip, GYH .
JOURNAL OF INTERNAL MEDICINE, 2003, 253 (01) :81-91
[8]   Endothelial damage and angiogenesis in hypertensive patients: Relationship to cardiovascular risk factors and risk factor management [J].
Felmeden, DC ;
Spencer, CGC ;
Belgore, FM ;
Blann, AD ;
Beevers, DG ;
Lip, GYH .
AMERICAN JOURNAL OF HYPERTENSION, 2003, 16 (01) :11-20
[9]   The biology of vascular endothelial growth factor [J].
Ferrara, N ;
DavisSmyth, T .
ENDOCRINE REVIEWS, 1997, 18 (01) :4-25
[10]  
Fosslien E, 2001, ANN CLIN LAB SCI, V31, P325